Security
CytoMed Therapeutics Limited Ordinary Shares · GDTC
GDTCNASDAQCommon stockCurrentCIK 1873093Updated Oct 26, 2026
Name history
CytoMed Therapeutics Pte. Ltd. · through Nov 30, 2022
GDTC price & chart
Loading TradingView…
NASDAQ:GDTC on TradingView ↗In the news
No coverage from other publishers is available.
Seeking Alpha
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossUSD | -3,107,812Source | -1,845,894Source | -3,132,851Source | -2,336,208Source |
| Additional Financial Items | ||||
| AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociatesSGD | -223,204Source | — | — | — |
| AdjustmentsForIncreaseDecreaseInTradeAccountPayableUSD | -132Source | -61,192Source | 83,512Source | 190,294Source |
| AdjustmentsForSharebasedPaymentsUSD | 539,855Source | — | — | — |
| GoodwillSGD | 355Source | 355Source | 355Source | 355Source |
| InterestPaidClassifiedAsFinancingActivitiesUSD | 16,258Source | 14,868Source | 35,407Source | 93,386Source |
| InterestReceivedClassifiedAsOperatingActivitiesUSD | — | 1,773Source | 75,031Source | 1,564Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD | 11,701Source | 7,171Source | 5,641Source | 5,636Source |
| ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivitiesUSD | — | — | — | 366Source |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesUSD | 50,769Source | 68,958Source | — | — |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesUSD | 29,935Source | 25,459Source | 25,001Source | 53,121Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 252,265Source | 50,872Source | — | — |
| Additional Financial Items | ||||
| AverageEffectiveTaxRatenumber | 0.17Source | 0.17Source | — | — |
| BasicEarningsLossPerShareUSD per share | -0.27Source | -0.16Source | -0.29Source | — |
| DeferredTaxExpenseIncomeSGD | 2,406,000Source | 1,740,000Source | 1,348,000Source | 972,230Source |
| DilutedEarningsLossPerShareUSD per share | -0.27Source | -0.16Source | -0.29Source | -0.3Source |
| EmployeeBenefitsExpenseUSD | 723,667Source | 453,321Source | 344,230Source | 157,160Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesSGD | 309,248Source | — | — | — |
| FinanceCostsUSD | 16,258Source | 14,868Source | 38,871Source | 93,386Source |
| ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillUSD | 4,161Source | — | — | — |
| IncomeTaxExpenseContinuingOperationsUSD | — | — | 495Source | 1,224Source |
| InterestExpenseUSD | 16,258Source | 14,868Source | 38,871Source | 93,386Source |
| InterestExpenseOnLeaseLiabilitiesSGD | 2,597Source | 629Source | 499Source | 896Source |
| NetForeignExchangeLossSGD | — | — | 170,311Source | 26,422Source |
| OtherEmployeeExpenseSGD | 860,835Source | 737,524Source | 642,533Source | 500,038Source |
| OtherIncomeSGD | 2,503Source | 5,358Source | 2,878Source | 6,028Source |
| OtherOperatingIncomeExpenseUSD | 528,592Source | 573,899Source | 609,341Source | 362,111Source |
| PostemploymentBenefitExpenseDefinedContributionPlansSGD | 172,622Source | 141,294Source | 117,283Source | 80,212Source |
| ProfessionalFeesExpenseSGD | 9,098Source | 35,040Source | 20,779Source | 317,613Source |
| ProfitLossAttributableToNoncontrollingInterestsUSD | — | -3,779Source | -208Source | -181Source |
| ProfitLossAttributableToOwnersOfParentUSD | -3,095,463Source | -1,842,115Source | -3,132,643Source | -2,336,027Source |
| ProfitLossBeforeTaxUSD | -3,107,812Source | -1,845,894Source | -3,132,356Source | -2,334,984Source |
| ResearchAndDevelopmentExpenseUSD | 1,724,469Source | 1,397,686Source | 1,204,952Source | 1,136,053Source |
| RevenueFromInterestUSD | 96,351Source | 232,521Source | 216,569Source | 1,564Source |
| ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodSGD | -6,391Source | 13,765Source | -31,198Source | -33,546Source |
Filing attachments
ex99-1.htm · 6-K · 2026-10-13
Exhibit 99.1 CytoMed Therapeutics Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency Singapore, October 9, 2026 - CytoMed Therapeutics Limited (the “Company”) (NASDAQ: GDTC), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived, cell-based allogeneic immunotherapies, today announced that on October 6, 2026, the Company received a notice from the staff of the N…
Read attachment ↗ex99-1.htm · 6-K · 2026-09-30
Exhibit 99.1 CYTOMED THERAPEUTICS LIMITED AND ITS SUBSIDIARIES UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS INDEX Unaudited Interim Condensed Consolidated Statements of Profit or Loss and Other Comprehensive Loss for the Six months ended June 30, 2025 and 2026 2 Unaudited Interim Condensed Consolidated Statements of Financial Positions as of December 31, 2025 and June 30, 2026 3 Unaudited Interim Condensed Consolidated Stat…
Read attachment ↗ex99-2.htm · 6-K · 2026-09-30
Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE SIX MONTHS ENDED JUNE 30, 2026 The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the unaudited interim condensed consolidated financial statements and the notes thereto, included as Exhibit 99.1 to this Report on Form 6-K. We also recommend that you read our discussion and analysis of financial condition and resul…
Read attachment ↗ex99-1.htm · 6-K · 2026-04-14
Exhibit 99.1 CytoMed Therapeutics Limited 1 Commonwealth Lane #08-22 Singapore 149544 PROXY STATEMENT AND NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To April the shareholders of 14, 2026 ─────────────────────────────────────── CytoMed Singapore Therapeutics Limited To our shareholders: It is my pleasure to invite you to our Annual General Meeting of Shareholders of CytoMed Therapeutics Limited (the “Company”) on May 22, 2026,…
Read attachment ↗ex99-2.htm · 6-K · 2026-04-14
Exhibit 99.2 Control Number of Registered Number: Shares: Shareholder: ──────────────────────────────────────────── CytoMed Therapeutics Limited 1 Commonwealth Lane, #08-22 Singapore 149544. PROXY Solicited on Behalf of the Board of Directors for the Annual General Meeting of Shareholders on May 22, 2026, at 12:00 P.M., Singapore time (May 22, 2026, at 12:00 A.M., Eastern Time) The undersigned hereby appoints Choo Chee Kong as proxy with full power of substitu…
Read attachment ↗ex99-1.htm · 6-K · 2026-01-28
Exhibit 99.1 CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress Singapore, (January 28, 2026) - CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumors, today issued a statement to address…
Read attachment ↗